Drug Trial Radar · NCT06082635
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
321
Actual
Start
Dec 14, 2023
Primary completion
Apr 30, 2026
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Sun Yat-Sen University Cancer Center
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
Conditions
- Non Small Cell Lung Cancer
Interventions
TGRX-326Drug
Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles
CrizotinibDrug
Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by independent review committee (IRC)Time frame: Every 8 weeks between Cycle 1 and Cycle 17, and every 12 weeks from Cycle 17 and onwards (every cycle is 28 days); an average of 1.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.